

# Program prevencije kardiovaskularnih bolesti u obiteljskoj medicini

**Prof.dr.sc. Biserka Bergman Marković**

**Prof.dr.sc. Katić Milica**

**Prof.dr.sc. Vesna Jureša**

**Prof.dr.sc. Sanja Blažeković Milaković**



Katedra za obiteljsku medicinu,  
Katedre za socijalnu medicinu i organizaciju zdravstvene  
zaštite

Škola narodnog zdravlja „Andrija Štampar”, Medicinski  
fakultet Sveučilišta u Zagrebu

Motovun 10.06.2014

# Moto predavanja


**Iako svaki drugi Hrvat umire od kardiovaskularnih bolesti,  
sustavna i jednoobrazna prevencija kadiovaskularnih  
bolesti ne postoji**




# KARDIOVASKULARNE BOLESTI RASTUĆI JAVNO ZDRAVSTVENI PROBLEM

## Smrtnost od KVB

## BND / stanovnik



Muller Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in CV mortality within  
• Europe. Eur Heart J 2008;29:1316-26



Map showing regional variation in European GDP (PPP) per capita in 2012. Figures from WorldBank 2014. •

# Smrtnost od kardiovaskularnih bolesti u Hrvatskoj

Hrvatsko zdravstveno statistički ljetopis, 2012

- 2012  
48,3%
- 2015  
?????
- 2020  
??????
- 
-

# Visoka stopa smrtnost od kardiovaskularnih bolesti u Hrvatskoj



**Zašto je to tako ?  
U čemu je problem?**

- Postoji li edukacija obiteljskih liječnika ?
- Postoje li smjernice (međunarodne, nacionalne) ?
- Kakav je stav zdravstvenih vlasti prema prevenciji ?
-

- Postoji li edukacija obiteljskih lječnika ?



# Edukacija obiteljske medicine

## Kontinuirana medicinska edukacija (KME)

Društvo nastavnika opće/obiteljske medicine (DNOOM)

- Kongresi
- Radionice
- Projekti

Katedra za obiteljsku medicinu

- Dodiplomksa nastava
- Poslijediplomska nastava
- Specijalizacija iz obiteljske medicine

2009

• 23.7.2014.



•

- Postoje li smjernice  
(međunarodne, nacionalne) ?



# Smjernice

- JNC 7 2003
- ECS/EHS 2003
- NCEP ATP III

• The European Task Force  
ESC/ EAS

## Smjernice za zbrinjavanje dislipidemija,

1 Reiner Ž., Capatano A.L., De Backer  
2 G. i sur., 2011  
3 2001,200,2400-2491.



European Heart Journal (2011) 32, 1769–1818  
doi:10.1093/eurheartj/ehr158

### ESC/EAS GUIDELINES



### ESC/EAS Guidelines for the management of dyslipidaemias

The Task Force for the management of dyslipidaemias of the  
European Society of Cardiology (ESC) and the European  
Atherosclerosis Society (EAS)

Developed with the special contribution of: European Association for Cardiovascular  
Prevention & Rehabilitation<sup>†</sup>

Authors/Task Force Members: Željko Reiner\* (ESC Chairperson) (Croatia),  
Alberico L. Catapano\* (EAS Chairperson)\* (Italy), Guy De Backer (Belgium),  
Ian Graham (Ireland), Marja-Riitta Taskinen (Finland), Olov Wiklund (Sweden),  
Stefan Agewall (Norway), Eduardo Alegria (Spain), M. John Chapman (France),  
Paul Durrington (UK), Serap Erdine (Turkey), Julian Halcox (UK), Richard Hobbs  
(UK), John Kekshus (Norway), Pasquale Perrone Filardi (Italy), Gabriele Riccardi  
(Italy), Robert F. Storey (UK), David Wood (UK).

ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees: Jeroen Bax (CPG Chairperson 2010–2012), (The Netherlands), Alec Vahanian (CPG Chairperson 2008–2010) (France), Angelo Auricchio (Switzerland), Helmut Baumgartner (Germany), Claudio Cecioni (Italy), Veronica Dean (France), Christi Deaton (UK), Robert Fagard (Belgium), Gerasimos Filippatos (Greece), Christian Funk-Brentano (France), David Hasdai (Israel), Richard Hobbs (UK), Arno Hoes (The Netherlands), Peter Kearney (Ireland), Juhani Knuuti (Finland), Philippe Kolh (Belgium), Therese McDonagh (UK), Cyril Moulin (France), Don Poldermans (The Netherlands), Bogdan A. Popescu (Romania), Željko Reiner (Croatia), Udo Sechtem (Germany), Peo Anton Sirnes (Norway), Michal Tendera (Poland), Adam Torbicki (Poland), Panos Vardas (Greece), Petr Widimsky (Czech Republic), Stephan Windecker (Switzerland)

Document Reviewers, Christian Funk-Brentano (CPG Review Coordinator) (France), Don Poldermans (Co-Review Coordinator) (The Netherlands), Guy Berkenboom (Belgium), Jacqueline De Graaf (The Netherlands), Olivier Descamps (Belgium), Nina Gotcheva (Bulgaria), Kathryn Griffith (UK), Guido Francesco Guida (Italy), Sadi Gulec (Turkey), Yaakov Henkin (Israel), Kurt Huber (Austria), Y. Antero Kesaniemi (Finland), John Lekakis (Greece), Athanasios J. Manolis (Greece), Pedro Marques-Vidal (Switzerland), Luis Masana (Spain), John McMurray (UK), Miguel Mendes (Portugal), Zurab Pagava (Georgia), Terje Pedersen (Norway), Eva Prescott (Denmark), Quiteria Rato (Portugal), Giuseppe Rosano (Italy), Susana Sans (Spain), Anton Stalenhoef (The Netherlands), Late Tokgozoglu (Turkey), Margus Viigimaa (Estonia), M. E. Wittekoek (The Netherlands), Jose Luis Zamorano (Spain).

\* Corresponding authors: Željko Reiner (ESC Chairperson), University Hospital Center Zagreb, School of Medicine, University of Zagreb, Salata 2, 10 000 Zagreb, Croatia. Tel: +385 1 492 0019, Fax: +385 1 481 8457, Email: reiner@hrc-zagreb.hr; Alberico L. Catapano (EAS Chairperson), Department of Pharmacological Science, University of Milan, Via Balzaretti, 9, 20133 Milan, Italy. Tel: +39 02 5031 8986, Email: Alberico.Catapano@unimi.it

<sup>†</sup>Other ESC entities having participated in the development of this document:

Associations: Heart Failure Association.

Working Groups: Cardiovascular Pharmacology and Drug Therapy, Hypertension and the Heart, Thrombosis.

The content of these European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Guidelines has been published for personal and educational use only. No

commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permissions can be requested upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC.

**Disclaimer:** The ESC Guidelines represent the views of the ESC and the EAS, were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patients, in consultation with that patient, and where appropriate and necessary the patient's guardian or carer. It is also the health professional's responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.

©2011 The European Society of Cardiology and the European Atherosclerosis Association. All rights reserved. For permissions please email: journals.permissions@oxp.com

# Nove smjernice ECS (2012)

Rujan  
2012

The diagram illustrates the European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). A large blue arrow points from the title "Nove smjernice ECS (2012)" at the top to the main document. A smaller blue arrow points from the document to a list of participating societies on the right.

**JOINT ESC GUIDELINES**

**European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)**

**The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)**

Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)<sup>†</sup>

**Authors/Task Force Members:** Jörg Perk (Chairperson) (Sweden)\*, G. Belotti (Italy), H. Goettner (Germany), Iain Graham<sup>1</sup> (Ireland), Željko Grm (Croatia), W.M. Mancia (Italy), M. Merschheuren<sup>1</sup> (The Netherlands), Christian Mazzucco (Germany), Paul Montravers<sup>1</sup> (France), Gudrun Boysen<sup>4</sup> (Denmark), R. Chioléro (Switzerland), Christi Deaton<sup>1</sup> (UK), Shah Ebrahim<sup>1</sup> (UK), Miles Giesen (Germany)<sup>5</sup>, Richard Hobbs<sup>1,7</sup> (UK), Arno Hoes<sup>7</sup> (The Netherlands), M. Kavurmacı<sup>8</sup> (Turkey), Alessandro Mezzani<sup>1</sup> (Italy), Eva Prescod (Sweden), Martin Scherer<sup>7</sup> (Germany), Mikko Syyvänen<sup>9</sup> (Finland), M. Scholte Op Reimer<sup>1</sup> (The Netherlands), Christiaan Vrinten (The Netherlands), and Peter Wood<sup>1</sup> (UK), Jose Luis Zamorano<sup>1</sup> (Spain), Faiez Zannad<sup>1</sup> (France).

**Other experts who contributed to parts of the guidelines:** Marie Therese Cooney (Ireland), ESC Committee for Practice Guidelines (CPG): Jeroen Bax (Chairman) (The Netherlands), H. Belotti (Italy), Claudio Cecconi (Italy), Veronica Dean (France), Christi Deaton (UK), Robert Fagard (Belgium), Christian Funck-Brentano (France), David Hasdai (Israel), Arno Hoes (The Netherlands), Paul Mancia (Italy), Juhani Knuuti (Finland), Philippe Kolh (Belgium), Theresa McDonagh (UK), Cyril Masse (Canada), Bogdan A. Popescu (Romania), Željko Reiner (Croatia), Udo Sechtem (Germany), Per Anton Michal Tendera (Poland), Adam Torbicki (Poland), Alec Vahanian (France), Stephan Windecker (Switzerland).

**Document Reviewers:** Christian Funck-Brentano (CPG Review Coordinator) (France), Per Anttonen (CPG Review Coordinator) (Norway), Victor Aboyan (France), Eduardo Alegria (Spain), and Per Lindahl (Sweden).

\* Corresponding author: Jörg Perk, School of Health and Caring Sciences, Linnaeus University, Stigbergsgatan 14, SE-391 82 Kalmar, Sweden. Tel: +46 78 643. Email: joerg.perk@lnu.se

<sup>†</sup> Other ESC entities having participated in the development of this document:  
Associations: European Association of Echocardiography (EAE), European Association of Percutaneous Cardiovascular Interventions (EPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA)  
Working Groups: Acute Cardiac Care, Cardiology, Cardiovascular Pharmacology and Drug Therapy, Hypertension and the Heart, Councils: Basic Cardiovascular Sciences, Cardiology Practice, Cardiovascular Imaging, Cardiovascular Nursing and Allied Professions, Cardiovascular Thrombosis, European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use of ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission to the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC.

**Disclaimer:** The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time of publication. They are not intended to be prescriptive and do not supersede individual professional judgment. The guidelines do not, however, override the professional judgment of the practitioner in the circumstances of the individual patient, in consultation with the patient, and where appropriate, guardian or carer. It is also the health professional's responsibility to verify the rules and regulations applicable to drug and devices at the time of publication.

The disclosure forms of the authors and reviewers are available on the ESC website [www.escardio.org/guidelines](http://www.escardio.org/guidelines).

© The European Society of Cardiology 2012. All rights reserved. For permissions please email: [journals.permissions@escardio.org](mailto:journals.permissions@escardio.org)

**European Society of Cardiology (ESC)**

**European Association for Cardiovascular Prevention & Rehabilitation (EACPR)**

**European Society of Hypertension (ESH)**

**International Society of Behavioral Medicine (ISBM)**

**European Heart Network (EHN)**

**European Association for the Study of Diabetes (EASD)**

**European Atherosclerosis Society (EAS)**

**International Diabetes Federation Europe (IDF-Europe)**

**European Society of General Practice/Family Medicine (ESGP/FM)/Wonca**

**European Stroke Initiative (EUSI)**


# Nacionalne smjernice za prevenciju KVB

• Ne postoje zajednički  
usaglašene  
smjernice  
svih društva

for

2003

# Nacionalni programi prevencije KVB OBITELJSKA MEDICNA



Program nije nikada zaživio,  
implementacija ne postoji



# Program prevencije KVB u obiteljskoj medicini, 2003:

- skupina primarne KV prevencije
- screening
- proaktivni pristup:  
LOM treba koristiti svaki kontakt s pacijentom za aktivno traženje
- osobna i obiteljska anamneze
- svi  $> 18$  godina jednom u 5 godina provjeriti čimbenike rizika za KV bolesti
  - glikemija
  - arterijski tlak,
  - uzimanje alkohola
  - pušenje
  - lipidemije
  - BMI

AKTIVNO TRAŽENJE

$>18$

# Prijedlog Nacionalnog programa prevencije KV bolesti u RH 2012

## Ciljna populacija

- sve osobe dobi  $\geq 40$  godina koje posjete svog LOM zbog bilo kojeg razloga



# Prijedlog Nacionalnog programa prevencije KV bolesti u RH, 2012

- Procjena učestalosti čimbenika rizika

•

•

# Prijedlog Nacionalnog programa prevencije KV bolesti u RH 2012

Dio elektronskog zdravstvenog zapisa (EZZ)

Provjeriti, izmjeriti i zabilježiti u e-karton - **OBVEZA UBILJEŽBE**

- osobna anamneza - **NAVIKE**
  - uzimanje alkohola
  - pušački status
  - provođenje tjelesne aktivnosti
- Fizikalni pregled
  - **visinu, težinu, IMT, opseg trbuha**
  - **srednju vrijednost arterijskog tlaka (2 mjerenja)**
- obiteljska anamneza
  - **rana KV smrtnost u obitelji (roditelji, braća)**

# Provjeriti i zabilježiti u e-karton

## **Laboratorijska analiza uzorka krvi:**

- Lipidni status
  - ukupnog kolesterol
  - HDL kolesterol
  - LDL kolesterol
  - Trigliceridi
- Glukoza u plazmi ( GUPnt) / HbA<sub>1</sub>C
- procjena 10-godišnjeg rizika fatalne KV bolesti prema SCORE-u
- 
-

# Prijedlog Nacionalnog programa prevencije KV bolesti u RH, 2012

- Procjena kvalitete rada
- (postizanje ciljnih vrijednosti), zbrinjavanje i praćenje
  - prema usaglašenim smjernicama europskih stručnih društva koje su prihvatile i krvatska stručna društva ( HKD, HDH, HDA)
  - 
  -

# POSTIZANJE CILJNIH VRIJEDNOSTI

Tijek intervencije	1 mj	3 mj	Postignuta ciljna vrijednost	3 mj	6 mj	12 mj	18 mj
Arterijski tlak	X			X	X	X	X
GUK natašte	X			X	X	X	X
KOL-uk		X			X		X
HDL		X			X		X
LDL		X			X		X
Trigliceridi		X			X		X
Urati		X				X	X
Visina	X				X	X	X
Težina	X				X	X	X
Opseg struka	X				X	X	X
Opseg bokova	X				X	X	X
Pušenje	X				X	X	X
Tjelesna aktivnost	X				X	X	X

# Prijedlog Nacionalnog programa prevencije KV bolesti u RH 2012

## Praćenje programa

- planira se i ugovara na godinu dana
- o provedbi izvještava svaka 3 mjeseca i završno na kraju godine
- 

## Način plaćanja

- plaćanje prema izvršenju,

Obuhvat populacije %	Simulacija %
< 50	0
50 - 69	50
70 - 80	70
>80	100

# Novi model ugovaranja primarne zdravstvene zaštite, 2013

## PANELI

### Stimulacija !!!!!

- Hipertenzija
- Dijabetes
- KOPB
- prevencija

•


## PROGRAMI PREVENCije KRONIČNIH BOLESTI

- za sada nema niti jedan

•

# Novi model ugovaranja primarne zdravstvene zaštite, 2013

## PENTAGRAM: veliki tim, udio prihoda



# KPI i QI

- **KPI i QI KPI (Key performance indicators)**
    - Propisivanje lijekova na Rp (potrošnja i smjernice)
    - Stopa bolovanja
    - Upućivanje u PZZ laboratorij
    - Upućivanje u skzz
    - Prijavljivanje zaraznih bolesti
  - **QI (Quality indicators)**
    - Klinički pokazatelji
    - Specifična područja (kardio i cerebrovaskularne bolesti, debljina, dijabetes, KOPB)
    - Organizacijski pokazatelji
- Jednostavni

  - Mjerljivi
  - Dohvatljivi iz e Kartona i CEZIH-a

## Novi model ugovaranja primarne zdravstvene zaštite, 2013



# Kakvu prevenciju KVB imamo ?



# Uloga obiteljske medicine u prevenciji KV bolesti

## Prevencija KVB DANAS

- Individualna

## Prevencija KVB SUTRA

- osmišljena
- sustavna
- programirana



# Preventivni pristup KVB u obiteljskoj medicini

- populacijski
- individualni pristup visokorizičnim skupinama
- kombinacija (koju WHO preporučuje)

•

•

# Preventivni pristup KVB u obiteljskoj medicini

Liječničke novine, 07.2013

## 1. Stimulacija NE prema pojedinačnom panelu

- ✓ Podatke panela -
  - pokupiti
  - evaluirati
  - vratiti liječniku obiteljske medicine - poboljšanje rada

## 2. Stimulacija prema zabilježbi učestalosti čimbenika rizika

Obuhvat populacije %	Simulacija %
< 50	0
50 - 69	50
70 - 80	70
>80	100

## 3. Stimulacija prema postizanju ciljnih vrijednosti čimbenika rizika



# Program prevencije KVB u RH

- Sveobuhvatan
  - nacionalni
  - multiprofesionalan

Zajednička aktivnost MZ, HZZO, HZJZ i obiteljske medicine

- 
-

# Pilot projekt programa prevencije kardiovaskularnih bolesti



# CRISIC-fm

## Cardiovascular risk and intervention study in Croatia-family medicine

(ISRCTN31857696)

- multicentrična, prospektivna, cluster-randomizirana, interventna, kohortna, kontrolirana studija
  - 59 LOM (response rate 71%)
  - Broj ispitanika N=2467 (response rate 78%)
  - Trajanje =18 mjeseci
  - 4 doktorske dizertacije
    - DOKAZANA UČINKOVITOST SUSTAVNE PROGRAMIRENE INTERVENCIJE LIJEČNIKA OBITELJSKE MEDICINE
    -

# Doktorska disertacija: Ksenija Kranjčević

„Učinkovitost intervencije na ukupni srčanožilni rizik u obiteljskoj medicini, uloga GFR u procjeni kardiovaskularnog rizika”, 2014

	Intervencija			P	Kontrola		
	2008.	2010.	Razlika		2008.	2010.	Razlika
SCORE							
Nizak	27,2	16,7	-10,5	0,900	24,2	12,8	-11,4
Umjereni	41,5	43,4	+ 1,9	0,461	38,5	38,3	- 0,2
Visoki	17,1	19,5	+ 2,4	0,822	20,1	19,2	- 0,9
Vrlo visoki	14,2	20,4	+ 6,2	<0,001	17,2	29,6	+12,4



# Doktorska disertacija: Ksenija Kranjčević

„Učinkovitost intervencije na ukupni srčanožilni rizik u obiteljskoj medicini, uloga GFR u procijeni kardiovaskularnog rizika”, 2014

	Intervencija			P	Kontrola		
	2008.	2010.	Razlika		2008.	2010.	Razlika
Hipertenzija	56,4	62,5	+6,1	0,014	61,7	72,6	+10,9
↑uk. kolesterol	75,6	78,9	+3,3	<0,001	76,5	75,3	- 1,2
↓HDL	17,3	21,5	+4,2	0,332	20,3	21,8	+ 1,5
↑ LDL	64,8	65,9	+1,07	<0,001	48,3	60,0	+11,7
pušenje	24,0	25,2	+1,2	0,094	21,7	21,2	- 0,5



# Doktorska disertacija: Ksenija Kranjčević

„Učinkovitost intervencije na ukupni srčanožilni rizik u obiteljskoj medicini, uloga GFR u procijeni kardiovaskularnog rizika”,

	Intervencija		P	Kontrola	
	2008.	2010.		2008.	2010.
	mean	mean		mean	mean
Sistolički RR	129,65	128,16	<0,001	129,82	132,65
Dijastolički RR	81,15	79,58	<0,001	80,73	81,67
Uk. kolesterol	5,94	5,64	0,584	5,75	5,67
HDL-kolesterol	1,51	1,48	0,287	1,48	1,45
LDL-kolesterol	3,63	3,35	0,136	3,42	3,27
Trigliceridi	1,92	1,74	0,014	1,94	1,95
ITM	28,71	28,49	<0,001	29,25	29,64



# Zaključak

- Sustavna, programirana prevencija kardiovaskularnih bolesti dokazano daje pozitivan rezultat
- 
-